GLP-1 Drugs Show Promise Beyond Weight Loss for Addiction Treatment

A class of medications designed to help people lose weight is now drawing serious attention from psychiatrists who wonder whether it might do something else entirely: interrupt the brain's reward system in ways that could treat behavioral addictions like gambling and compulsive shopping.

Dr. Carolina Haass-Koffler, an associate professor of psychiatry at Brown University, has begun examining this possibility. The drugs in question—GLP-1 receptor agonists, which include medications like semaglutide—were developed to regulate blood sugar and appetite. But emerging research suggests they may also influence dopamine pathways, the neural circuits that drive compulsive behavior and reinforce addictive patterns.

The mechanism is straightforward in theory. These medications appear to dampen the brain's reward response, which is why they help people feel satisfied with smaller portions of food. That same dampening effect, researchers hypothesize, could reduce the psychological pull of gambling, shopping, or other behaviors that activate the same reward centers. A person struggling with the urge to place bets or make unnecessary purchases might experience less of the dopamine surge that makes those behaviors feel irresistible.

Haass-Koffler's work represents a broader shift in how addiction researchers think about treatment. For decades, behavioral addictions—as opposed to substance addictions—have been harder to address pharmacologically. Talk therapy and cognitive behavioral interventions remain the standard approaches. But if GLP-1 drugs can reliably modulate reward pathways, they could offer a new tool, particularly for people who have not responded to existing treatments.

The evidence so far remains preliminary. Most of what researchers know comes from animal studies, case reports, and the observable effects of these drugs on eating behavior. No large-scale clinical trials have yet established whether GLP-1 medications are safe or effective for treating gambling addiction, shopping compulsion, or other behavioral disorders. The drugs carry their own side effects—nausea, vomiting, and in rare cases, pancreatitis—which would need to be weighed against any benefit.

Still, the possibility has captured the attention of the psychiatric community. If the hypothesis holds, it could reshape how clinicians approach patients whose lives are derailed by compulsive behavior. It could also raise new questions about off-label use, insurance coverage, and whether medications developed for one condition should be prescribed for another without robust evidence.

For now, Haass-Koffler and her colleagues are calling for the kind of rigorous testing that would either confirm or refute the theory. Clinical trials would need to measure not just whether patients gamble or shop less, but whether any improvement is durable, whether side effects are tolerable, and whether the drugs work better for some people than others. The research is in its infancy, but the direction is clear: psychiatry is beginning to ask whether a weight-loss drug might also be a tool for breaking the grip of behavioral addiction.